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n higher eukaryotic cells, the nucleolus is a nuclear
compartment assembled at the beginning of interphase,
maintained during interphase, and disorganized during
mitosis. Even if its structural organization appears to be
undissociable from its function in ribosome biogenesis, the
mechanisms that govern the formation and maintenance of
the nucleolus are not elucidated. To determine if cell cycle
regulators are implicated, we investigated the putative role
of the cyclin-dependent kinases (CDKs) on ribosome
biogenesis and nucleolar organization. Inhibition of
CDK1–cyclin B during mitosis leads to resumption of
rDNA transcription, but is not sufﬁcient to induce proper
I
 
processing of the pre-rRNA and total relocalization of the
processing machinery into rDNA transcription sites. Similarly,
at the exit from mitosis, both translocation of the late
processing machinery and pre-rRNA processing are impaired
in a reversible manner by CDK inhibitors. Therefore, CDK
activity seems indispensable for the building of functional
nucleoli. Furthermore, inhibition of CDKs in interphasic cells
also hampered proper pre-rRNA processing and induced a
dramatic disorganization of the nucleolus. Thus, we propose
that the mechanisms governing both formation and
maintenance of functional nucleoli involve CDK activities
and couple the cell cycle to ribosome biogenesis.
 
Introduction
 
The nucleolus is a model of an active and dynamic nuclear
domain and plays a major role in compartmentalization of
nuclear function. In higher eukaryotic cells, the nucleolus
assembles at the exit from mitosis and is functionally active
throughout interphase. Its major function, i.e., ribosome
biogenesis, requires rDNA transcription, pre-rRNA processing,
and assembly of the mature rRNAs with ribosomal proteins
(Hadjiolov, 1985). The nucleolus was more recently reported
to be a plurifunctional nuclear domain (Olson et al., 2000)
involved in cell cycle control (Visitin and Amon, 2000),
nuclear protein export (Zolotukhin and Felber, 1999), and the
aging process (Guarente, 1997), and to contain components of
signal recognition particles (Politz et al., 2000). Therefore, it
is most likely that the existence of a fully active nucleolus is
not only essential for ribosome production, but also for
control of cell survival and cell proliferation (Carmo-Fonseca et
al., 2000).
Nucleoli are generally composed of three morphologically
distinct subdomains: the fibrillar centers (FCs),* the dense
fibrillar component (DFC), and the granular component
(GC) (Hadjiolov, 1985). The prevailing model is that the
subdomains reflect the vectorial process integrating the
47S pre-rRNA in its maturation pathway, and consequently,
the nucleolus is proposed to be “an organelle formed by the act
of building a ribosome” (Mélèse and Xue, 1995). How-
ever, there is presently no information on the mechanisms
controlling the coordination between the different steps of
ribosome biogenesis, in particular the coordination between
rDNA transcription and 47S pre-rRNA processing (Allmang et
al., 1999), and what nucleolar organization actually reflects.
It is well established that blockage of rDNA transcription
induces nucleolar disassembly and segregation of the nucleolar
machineries (Hadjiolov, 1985). However, we do not know if
the maintenance of an organized nucleolar compartment
throughout interphase is only dependent on pre-rRNA
synthesis. Indeed, nucleolar fragmentation can be induced
without direct interaction with rDNA transcription (Sinclair
et al., 1997).
Ribosome biogenesis involves several machineries dedicated
to rDNA transcription and processing of the 47S pre-rRNA
into 18S, 5.8S, and 28S mature rRNAs (Scheer and Hock,
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1999; Shaw and Jordan, 1995). rDNA transcription is de-
pendent on RNA polymerase (pol) I and requires at least
two factors in addition to active pol I, i.e., the upstream
binding factor (UBF) and the promoter selectivity factor,
SL1 (Moss and Stefanovsky, 1995; Grummt, 1999). Pro-
cessing of the 47S pre-rRNA is under the control of sev-
eral RNP complexes involving small nucleolar RNAs (sno-
RNAs). This activity is ordered from the early step of
processing in the 5
 
 
 
 external transcribed spacer (ETS) to the
last steps, the internal transcribed spacer 2, and 5.8S pro-
cessing (Tollervey, 1996).
During mitosis, the nucleolar activity is abolished and nu-
cleoli are no longer maintained. The rDNA transcription
machinery remains assembled in an inactive state at the level
of nucleolar organizer regions (NORs), i.e., in chromosomal
sites where rDNAs are also clustered (Roussel et al., 1996).
Conversely, the processing machinery does not remain in
the vicinity of the rDNAs. Indeed, proteins involved in pre-
rRNA processing, such as fibrillarin, nucleolin, Nop52, and
protein B23, are located at the periphery of chromosomes
during mitosis and are recruited in prenucleolar bodies
(PNBs) scattered throughout the nucleus in early G1 (Ji-
ménez-Garcia et al., 1994; Savino et al., 1999; Dundr et al.,
2000). In addition to proteins, PNBs contain snoRNAs in-
volved in pre-rRNA processing such as U3, U8, and U14
snoRNAs (Gautier et al., 1994; Jiménez-Garcia et al., 1994;
Dousset et al., 2000). Interestingly, it has been proposed
that different types of PNBs exist, containing complexes
dedicated to early or late processing events, and addressed to
the forming nucleoli with different kinetics (Westendorf et
al., 1998; Savino et al., 1999, 2001). These observations
suggest a spatio-temporal order in the formation of PNBs
and raise the possibility that at the M/G1 transition, the re-
cruitment of the processing machinery to the forming nucle-
oli is regulated.
Even if a general linkage between nucleolar function and
cell cycle regulation has not yet been established, rDNA
transcription is known to be regulated in a cell cycle–depen-
dent manner. On one hand, rDNA transcription is repressed
at mitosis by the cyclin-dependent kinase (CDK)1–cyclin
B-directed phosphorylation of components of the rDNA
transcription machinery (Heix et al., 1998; Sirri et al., 2000).
On the other hand, the increase of rDNA transcription dur-
ing G1 progression appears to depend on phosphorylation
of UBF by G1-specific CDK–cyclin complexes (Voit et al.,
1999). Moreover, highly proliferating cancer cells with de-
regulated cell cycle controls also exhibit modified rDNA
transcription activity. The retinoblastoma protein pRb
which suppresses cell proliferation can also suppress the pol I
activity by direct interaction with UBF (Hannan et al.,
2000). Nevertheless, because rDNA transcription can be
disconnected from pre-rRNA processing by in vivo inhibi-
tion of the CDK1–cyclin B pathway in mitotic cells (Sirri et
al., 2000), it remains to be elucidated if ribosome produc-
tion is regulated not only at the rDNA transcription level,
but also through pre-rRNA processing. Here we investigate
the role of CDKs on ribosome biogenesis, and on the forma-
tion and maintenance of the nucleolus. The results establish
that pre-rRNA processing is controlled by CDKs through-
out the cell cycle. Interfering with the pre-rRNA processing
pathway induces the redistribution of nucleolar machineries
and disorganization of the functional nucleolus.
 
Results
 
Inhibition of the CDK1–cyclin B pathway in mitotic 
cells induces the relocalization of fibrillarin at the
level of NORs, but not that of Nop52
 
By inhibiting the CDK1–cyclin B pathway, we established
that rDNA transcription may be restored in mitotic cells but
not proper pre-rRNA processing (Sirri et al., 2000). Because
the processing machinery does not remain associated with
rDNAs during mitosis, the pre-rRNA processing defect
could be due to the absence or abnormal targeting of the
processing machinery to rDNA transcription sites. To test
this hypothesis, we investigated the distribution of fibrillarin
and Nop52 (Fig. 1) involved in early and late pre-rRNA
processing events, respectively (Savino et al., 1999), using
the experimental approach described previously (Sirri et al.,
2000), i.e., colchicine-arrested mitotic HeLa cells treated or
not with roscovitine, a highly selective inhibitor of CDKs
(De Azevedo et al., 1997; Meijer et al., 1997). When
CDK1–cyclin B was inhibited by roscovitine, fibrillarin,
which is normally observed in the cytoplasm and enriched at
the chromosome periphery (Fig. 1 b), was partly relocated in
a few spots on the chromosomes (Fig. 1 e). Nop52 colocal-
ized with fibrillarin in colchicine-arrested mitotic HeLa cells
(Fig. 1, compare b with c). Roscovitine treatment also in-
duced an important relocalization of Nop52 (Fig. 1, com-
pare c with f) that now appeared as numerous small dots on
the chromosome periphery which are most probably the
PNBs observed in mitotic cells in telophase. To precisely de-
fine the relocalization of fibrillarin, UBF used as marker of
NORs, and fibrillarin were localized in the same mitotic
cells treated with roscovitine. The fluorescent patterns de-
tected for fibrillarin and for UBF (Fig. 1, g–i) showed that
fibrillarin relocalized at NORs, i.e., in chromosomal sites
where rDNA transcription is restored after inhibition of the
CDK1-cyclin B pathway. The comparison between the
fibrillarin (Fig. 1 e) and Nop52 labellings (Fig. 1 f) showed
that contrary to fibrillarin the relocalization of Nop52 in
sites of resumption of rDNA transcription seemed not to
only depend on the CDK1-cyclin B activity. Similar results
were observed in HeLa cells overexpressing fibrillarin or
Nop52 and in the parental HeLa cell line. The absence of re-
localization of Nop52 at the level of sites where rDNA tran-
scription restarts cannot be explained by different kinetics.
Indeed, similar results to those shown in Fig. 1 obtained af-
ter 1 h of treatment were obtained in mitotic HeLa cells
treated with roscovitine for 3 h (unpublished data).
 
In cells proceeding through M/G1 transition, CDK 
inhibitor-treatment does not interfere with 
relocalization of fibrillarin at the level of rDNA 
transcription sites, but blocks relocalization of Nop52 
and impairs formation of nucleoli
 
To determine the effect of roscovitine on the localization of
fibrillarin and Nop52 at the exit from mitosis, metaphase-
synchronized HeLa cells were treated or not treated with 75 
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M roscovitine for 90 min, i.e., when cells proceeded
through and exited from mitosis. Search for both proteins
was then undertaken and transcription revealed by in situ
transcription assays. As shown in Fig. 2, independently of
roscovitine, cells proceeded through mitosis and appeared
after 90 min as actively transcribing early G1 cells. As al-
ready published (Savino et al., 1999, 2001), in early G1 con-
trol cells, fibrillarin (Fig. 2, a–d) translocated to rDNA tran-
scription sites (Fig. 2, compare c with d) in the reformed
nucleoli (Fig. 2 a), and Nop52 (Fig. 2, i–l) appeared mainly
relocalized in the reformed nucleoli (Fig. 2, compare i, k,
and l) with a minor part still localized in PNBs (Fig. 2 l).
When cells exited from mitosis in the presence of rosco-
vitine, part of the fibrillarin (Fig. 2, e–h) relocalized at the
level of rDNA transcription sites (Fig. 2, compare g with h),
whereas Nop52, absent from rDNA transcription sites, ap-
peared in small dots in the nucleus (Fig. 2, compare o with
p). Moreover, in the roscovitine-treated cells, no reformed
nucleolus was visible (Fig. 2, compare e with g, and m with
o), showing that rDNA transcription is not sufficient to in-
duce formation of nucleoli visible by phase contrast, and
that resumption of rDNA transcription and formation of
nucleoli may be uncoupled. As assessed by microscope ob-
servations and localization of fibrillarin and Nop52 (unpub-
lished data), this effect on the formation of nucleoli could be
induced by treatment with other CDK inhibitors, olomou-
cine, alsterpaullone, and purvalanol. Conversely, the nega-
tive control iso-olomoucine and U0126, a selective and po-
tent inhibitor of mitogen-activated protein kinase kinase
and consequently of extracellular signal-regulated kinase
(ERK)1/2, caused no obvious effect on nucleologenesis.
To ascertain that CDK inhibitors actually impair the for-
mation of nucleoli at the exit from mitosis and to rule out
the possibility that the absence of formation of nucleoli oc-
curred as a consequence of an effect of CDK inhibitors on
late mitotic events, metaphase-synchronized HeLa cells were
treated (Fig. 3, e–h) or not treated (Fig. 3, a–d) with 75 
 
 
 
M
roscovitine for 90 min. Cells appearing as early G1 cells were
cultured for an additional 90 min after removal (Fig. 3, i–l)
or without removal (Fig. 3, m–p) of roscovitine. The obser-
vation by phase contrast and the detection of fibrillarin and
Nop52, proteins known to be localized in nucleoli during
interphase, in the same cells make it possible to follow the
formation of nucleoli and the correct localization of these
Figure 1. Roscovitine treatment 
induces relocalization of fibrillarin at 
the level of NORs but not that of Nop52 
in colchicine arrested mitotic HeLa 
cells. Stably transfected Nop52-GFP 
HeLa cells blocked in mitosis by
colchicine treatment were treated (d–f) 
or not (a–c) with 75  M roscovitine for
1 h. The cells were processed to label 
fibrillarin (b and e) and to observe 
Nop52-GFP (c and f). To precisely locate 
fibrillarin in roscovitine-treated mitotic 
cells, both fibrillarin (h) and UBF (i) were 
simultaneously labeled in untransfected 
HeLa cells treated with 75  M roscovitine 
for 1 h (g–i). Fibrillarin and Nop52 
which are normally observed in the
cytoplasm and enriched at the
chromosome periphery in mitotic cells 
(b and c) were largely relocated after 
roscovitine treatment (compare b with e, 
and c with f). Fibrillarin was then mainly 
localized in spots (e and h) corresponding 
to the NORs, where UBF is localized 
(compare h with i). Nop52 was observed 
in numerous small dots on the
chromosome periphery (f). Arrow (d)
indicates the cell for which enlargements 
are shown (d–f, insets). Bar, 10  m. 
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two nucleolar proteins. As expected from results shown in
Fig. 2, contrary to control cells (Fig. 3, a–d) for which both
Nop52 and fibrillarin were translocated to reformed nucleoli
(Fig. 3, compare a and c with d), cells treated by roscovitine
exited from mitosis without apparent formation of nucleoli
(Fig. 3, compare a with e). The absence of formation of nu-
cleoli is also argued by the fact that Nop52 and fibrillarin
did not localize in the same sites (Fig. 3, compare g with h).
More interestingly, the effect caused by the roscovitine treat-
ment was reversible. Indeed, 90 min after the removal of ros-
covitine, it was possible to observe reformed nucleoli in
which both Nop52 and fibrillarin were localized (Fig. 3, i–l).
Reversion was not observed when cells were maintained for
90 min more in roscovitine containing culture medium (Fig.
3, m–p) and therefore appeared actually to be due to the re-
moval of the CDK inhibitor.
 
CDK inhibitor-treatment interferes with the restoration 
of pre-rRNA processing at the exit from mitosis and 
leads to the accumulation of the 46S pre-rRNA
 
To analyze the possible effect of roscovitine on processing of
the newly synthesized pre-rRNA when mitotic repression of
rDNA transcription is normally abolished, rRNA synthesis
was followed in synchronized cells during exit from mitosis.
Metaphase-synchronized HeLa cells were metabolically la-
beled with [
 
32
 
P]orthophosphate in the absence (Fig. 4 A)
and presence (Fig. 4 B) of 75 
 
 
 
M roscovitine, and the newly
synthesized RNAs were analyzed every 30 min up to 120
min, i.e., when cells proceeded through and exited from mi-
tosis. As assessed by microscope observations, independently
of roscovitine, most cells appeared in telophase at 30 min
(unpublished data) and the mitotic repression of rDNA
transcription was being released (Fig. 4, A and B, lane e). In
Figure 2. Roscovitine does not interfere with relocalization of fibrillarin at the level of rDNA transcription sites but blocks relocalization 
of Nop52 and impairs formation of nucleoli at the exit from mitosis. Metaphase-sychronized HeLa cells were treated (e–h and m–p) or not 
treated (a–d and i–l) with 75  M roscovitine for 90 min. The cells were processed to detect transcription activity (c, g, k, and o), and to label 
fibrillarin (d and h) and Nop52 (l and p). They were analyzed by phase-contrast (a, e, i, and m) and DAPI staining (b, f, j, and n). Cells treated 
or not with roscovitine proceeded through mitosis and appeared after 90 min as actively transcribing early G1 cells. (a–d) In early G1 control 
cells, fibrillarin relocalized at rDNA transcription sites (compare c with d) in the reformed nucleoli (a), and (i–l) Nop52 appeared mainly 
relocalized in the reformed nucleoli (compare i, k, and l) with a minor part still localized in PNBs (l). In roscovitine-treated cells, part of the 
fibrillarin relocalized at rDNA transcription sites (compare g with h), whereas Nop52, absent from rDNA transcription sites, appeared as 
small dots in the nucleus (compare n, o, and p). In the roscovitine-treated cells no reformed nucleolus was visible (e and m). Bar, 10  m. 
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untreated cells, the 
 
32
 
P-labeled unprocessed 47S pre-rRNA
(reflecting resumption of rDNA transcription) appeared and
increased concomitantly with the partially processed or ma-
ture 
 
32
 
P-labeled rRNAs (reflecting pre-rRNA processing)
(Fig. 4 A, e–h). Consequently, processing of the newly syn-
thesized pre-rRNA appears not to be delayed with respect to
its synthesis when cells exit from mitosis. Conversely, in the
presence of roscovitine, resumption of rDNA transcription
at the exit from mitosis led to the accumulation of 46S pre-
rRNA (Fig. 4 B). The strong defect in pre-rRNA processing
in the presence of roscovitine was also observed by the ab-
sence of the 
 
32
 
P-labeled 45S pre-rRNA and the weak increase
of the levels of 
 
32
 
P-labeled mature 28S and 18S rRNAs (Fig.
4, compare A with B, lanes e–h).
 
Interphase nucleoli are no longer maintained after 
CDK inhibitor-treatment
 
The formation of nucleoli could be prevented by CDK in-
hibitor treatments, and therefore appeared as a regulated pro-
cess. Consequently, it may be asked whether the same treat-
 
ments could modify interphasic nucleoli. To answer this
question, the localization of both fibrillarin and UBF and of
both Nop52 and UBF was performed in asynchronous inter-
phasic HeLa cells treated or not for 2 h with 75 
 
 
 
M rosco-
vitine (Fig. 5). In control cells, the detection of both fibril-
larin and UBF (Fig. 5, a–e), and Nop52 and UBF (Fig. 5,
k–o) showed that these proteins are localized in nucleoli eas-
ily identifiable by phase contrast (Fig. 5, e and o). Rosco-
vitine treatment led to dramatic modifications of the nucleoli
as observed by phase contrast (Fig. 5, compare e with j and o
with t) whatever the stage of interphase of the cells. Nucle-
olar proteins were now detected in at least two kinds of nu-
clear bodies as visible by phase contrast. UBF and fibrillarin
appeared mainly in the same small nuclear bodies (Fig. 5,
f–j), whereas Nop52 appeared as components of larger nu-
clear bodies (Fig. 5, p–t). The two kinds of nuclear bodies
were easily distinguishable by comparing the localizations of
Nop52 and UBF (Fig. 5, q–s). Interestingly, this disorgani-
zation of nucleoli obtained after roscovitine treatment was
completely reversed 2 h after removal of roscovitine and
Figure 3. The roscovitine effects on the relocalization of Nop52 and on the formation of nucleoli at the exit from mitosis are both reversible. 
Stably transfected Nop52-GFP HeLa cells synchronized in metaphase were treated (e–h) or not treated (a–d) with 75  M roscovitine for 90 
min. Roscovitine-treated cells were cultured for an additional 90 min without (i–l) or with roscovitine (m-p). The cells were analyzed by 
phase-contrast (a, e, i, and m), DAPI staining (b, f, j, and n), Nop52-GFP observation (c, g, k, and o), and fibrillarin labeling (d, h, l, and p). In 
untreated cells (a–d), Nop52 and fibrillarin were mainly localized in the reformed nucleoli (compare a, c, and d). Roscovitine-treated cells exited 
from mitosis without apparent formation of nucleoli (compare a with e) and without gathering of Nop52 and fibrillarin in the same sites (compare 
g with h). Interestingly, 90 min after removal of roscovitine, nucleoli were formed, in which both Nop52 and fibrillarin were localized (i–l).
Reversion was not observed when cells were cultured for an additional 90 min in roscovitine containing medium (m–p). Bar, 10  m. 
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could be induced by treatment with other CDK inhibitors
(unpublished data). Indeed, olomoucine, alsterpaullone, and
purvalanol caused similar effects on the nucleoli as assessed
by microscope observations and localization of fibrillarin and
Nop52, but not U0126 used at concentrations up to 200
 
 
 
M for 3 h and the negative control iso-olomoucine used at
the same concentration as olomoucine.
 
The organization of the interphase nucleoli is rapidly 
modified after roscovitine treatment
 
The nucleolar organization in asynchronous interphasic
HeLa cells treated with roscovitine was examined by electron
microscopy. Already after 30 min of roscovitine treatment,
the arrangement of the three main nucleolar subdomains visi-
ble by electron microscopy was strongly modified (Fig. 6 A)
when compared with control cells (Fig. 6 B). After rosco-
vitine, FCs were only partly surrounded by the DFC, and the
disorganization of the GC was visible. Interestingly, new
structures formed in continuity with the remaining DFC
(Fig. 6 A, arrow) and close to the FC. These new structures
corresponded to densely packed granules distributed in tra-
baeculae. When the roscovitine treatment was prolonged for
2 h, these new dense structures were still visible in the prox-
imity of FCs, but also far from FCs indicating a dispersion of
these structures in the nucleus (unpublished data).
 
CDK inhibitor treatment reduces the generation 
of mature rRNAs by interfering with both 
rDNA transcription and pre-rRNA 
processing in interphasic cells
 
To determine the effects of CDK inhibitor treatment on nu-
cleolar activities, asynchronous interphasic HeLa cells were
metabolically labeled with [
 
32
 
P]orthophosphate in the ab-
sence or presence of a CDK inhibitor (Fig. 7 A). Cells were
treated without CDK inhibitor (Fig. 7 A, lanes a
 
 
 
–c
 
 
 
), with
75 or 25 
 
 
 
M roscovitine (Fig. 7 A, lanes d
 
 
 
–f
 
 
 
 and g
 
 
 
–i
 
 
 
, re-
spectively), with 250 
 
 
 
M olomoucine (Fig. 7 A, lanes j
 
 
 
–l
 
 
 
),
or with 250 
 
 
 
M iso-olomoucine used as negative control
(Fig. 7 A, lanes m
 
 
 
–o
 
 
 
), and the newly synthesized RNAs an-
alyzed after increasing times up to 3 h. The 
 
32
 
P-labeled 47-
45S pre-rRNAs and 
 
32
 
P-labeled 28S and 18S mature rRNAs
were quantified to compare the levels of the unprocessed
pre-rRNAs and processed rRNAs (Fig. 7 B). Considering
that the inhibitory activity of roscovitine is about 10 times
greater than that of olomoucine, similar results were ob-
tained with both CDK inhibitors (Fig. 7 A, compare lanes
g
 
 
 
–i
 
 
 
 with j
 
 
 
–l
 
 
 
). It was first noticeable that the levels of 
 
32
 
P-
labeled 28S and 18S mature rRNAs decreased in CDK in-
hibitor–treated interphasic cells (Fig. 7, A and B), showing
that synthesis of mature rRNAs was partially inhibited. In-
terestingly, the variations observed after CDK inhibitor
treatment were not explainable only by a decrease in rDNA
transcription. Indeed, the level of 
 
32
 
P-labeled 47-45S pre-
rRNAs was not significantly affected and did not vary in the
same proportion as the 
 
32
 
P-labeled mature rRNAs as partic-
ularly obvious after 75 
 
 
 
M roscovitine treatment (Fig. 7, A
and B, compare Control with 75 
 
 
 
M Rosc). Therefore, the
decrease in the generation of mature rRNAs most likely in-
volved not only a partial inhibition of rDNA transcription
but also a defect in pre-rRNA processing.
Figure 4. Roscovitine treatment leads to accumulation of 46S 
pre-rRNA at exit from mitosis. (A) Metaphase-synchronized HeLa 
cells were metabolically labeled with [
32P]orthophosphate in the 
absence and (B) in the presence of 75  M roscovitine and the RNAs 
isolated and analyzed at 30 min (lanes a and e), 60 min (lanes b and 
f), 90 min (lanes c and g), and 120 min (lanes d and h), i.e., during 
the M/G1 transition. (A and B, lanes a–d) RNAs were resolved in 
parallel on the same 1.2% agarose formaldehyde gel to discriminate 
between 47S, 46S, and 45S pre-rRNA and detected by ethidium 
bromide staining. (A and B, lanes e–h) Newly synthesized RNAs
detected after autoradiography. In the absence of roscovitine the 
32P-labeled unprocessed 47S pre-rRNA appeared and increased 
concomitantly with the 
32P-labeled partially processed or mature 
rRNAs (A, lanes e–h). In roscovitine-treated cells, the newly 
synthesized 46S pre-rRNA accumulated and no 
32P-labeled 45S 
pre-rRNA was detectable (B, lanes e–h). The levels of 
32P-labeled 
mature 28S and 18S rRNAs only slightly increased (compare B with 
A, lanes e–h). 
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The CDK inhibitor–induced defect in pre-rRNA 
processing leads to an increase in 46S pre-rRNA 
and to the disappearance of the 45S
pre-rRNA in a fully reversible manner
 
To better define the effects of CDK inhibitor treatment on
pre-rRNA processing, interphasic HeLa cells were metaboli-
cally labeled for 2 h with [
 
32
 
P]orthophosphate in the absence
(Fig. 8 A, lanes a and d) or presence of 25 
 
 
 
M (Fig. 8 A,
lanes b and e) or 75 
 
 
 
M (Fig. 8 A, lanes c and f) roscovitine,
and the RNAs resolved on a 1.2% agarose formaldehyde gel
to discriminate between 47S, 46S, and 45S pre-rRNA. As
mentioned above, roscovitine altered the generation of 28S
and 18S mature rRNAs. The decrease of the newly synthe-
sized mature rRNAs could not be explained only by partial
inhibition of rDNA transcription. Indeed, analysis of the
 
32
 
P-labeled rRNAs showed that with both inhibitor concen-
Figure 5. Interphase nucleoli are no longer maintained after roscovitine treatment. Stably transfected fibrillarin-GFP and Nop52-GFP HeLa 
cells were treated (f–j and p–t, respectively) or not (a–e and k–o, respectively) with 75  M roscovitine for 2 h. Interphasic cells were analyzed 
by DAPI staining (a, f, k, and p), fibrillarin-GFP (b and g) or Nop52-GFP observation (l and q), UBF labeling (c, h, m, and r), and phase-contrast 
(e, j, o, and t). In control cells, fibrillarin (b), Nop52 (l), and UBF (c and m) were localized in nucleoli easily identifiable by phase contrast 
(compare b–e and l–o). The roscovitine treatment led to dramatic modifications of the nucleoli as observed by fibrillarin labeling (compare b 
with g), Nop52 labeling (compare l with q), UBF labelling (compare c with h, and m with r), and phase contrast (compare e with j, and o with 
t). Fibrillarin and UBF were now mainly localized in small nuclear bodies (i–j, arrowheads) but not colocalized as seen by merging both labellings 
(i). Nop52 and UBF were localized in different nuclear bodies as seen by comparing superimposition of both labellings to phase contrast 
(s and t, arrowheads). Bar, 10  m. 
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trations the 
 
32
 
P-labeled 47S and 46S pre-rRNAs were not
decreased in the same proportions as the 28S and 18S
rRNAs. In particular, the 
 
32
 
P-labeled 46S pre-rRNA increased
(Fig. 8 A, lanes e and f) showing that processing of 46S pre-
rRNA into 45S pre-rRNA occurred less efficiently. Logi-
cally, the partially processed 45S pre-rRNA present at a high
level in control cells was no longer detectable in treated cells
(Fig. 8 A, compare lane d with lanes e and f). The pre-rRNA
processing defect was also visible by the modification in the
ratio between the 32S and 30S pre-rRNAs (Fig. 8 A, com-
pare lane d with lanes e and f). These results were confirmed
by Northern blot analyses carried out on interphasic HeLa
cells treated for increasing times up to 2 h with 75 
 
 
 
M ros-
covitine (Fig. 8 B). RNAs were analyzed using 
 
32
 
P-labeled
rDNA probes recognizing the 45-47S pre-rRNAs (Fig. 8 B,
5
 
 
 
-ETS core), the 46S-47S pre-rRNAs (Fig. 8 B, 3
 
 
 
-ETS),
and the unprocessed 47S pre-rRNA (Fig. 8 B, 5
 
 
 
-ETS
 
leader). The results obtained with the 5
 
 
 
-ETS core probe
showed that the 45-47S pre-rRNA species globally increased
with the duration of roscovitine treatment and that the 45S
pre-rRNA detected by the 5
 
 
 
-ETS core probe (Fig. 8 B, 5
 
 
 
-
ETS core, *) but not detected with the 3
 
 
 
-ETS and 5
 
 
 
-ETS
leader probes rapidly disappeared. The global increase de-
tected using the 5
 
 
 
-ETS core probe was due to the increase
of the 46S pre-rRNA. Indeed, the labeling obtained with the
3
 
 
 
-ETS probe recognizing both 46S and 47S pre-rRNA rap-
idly increased after roscovitine treatment (Fig. 8 B, 3
 
 
 
-ETS),
whereas the level of the unprocessed 47S pre-rRNA revealed
specifically by the 5
 
 
 
-ETS leader probe (Fig. 8 B, 5
 
 
 
-ETS
leader) did not significantly increase as assessed by quantifi-
cation (unpublished data). Therefore, it seems likely that
roscovitine interferes with pre-rRNA processing in interpha-
sic cells and leads to a rapid increase of the 46S pre-rRNA
and to the disappearance of the 45S pre-rRNA.
However, to definitively establish that pre-rRNA process-
ing is impaired in the presence of roscovitine and to verify
the reversibility of the pre-rRNA processing defect, inter-
phasic HeLa cells were pulse-labeled for 2 h with [
 
32
 
P]ortho-
phosphate in the presence of 75 
 
 
 
M roscovitine and the
 
32
 
P-labeled RNAs analyzed after a chase in nonradioactive
medium containing (Fig. 9 B) or not containing 75 
 
 
 
M ros-
covitine (Fig. 9 A) for increasing times up to 4 h. In the ab-
sence of roscovitine during the chase, restoration of proper
pre-rRNA processing, and residual 
 
32
 
P incorporation rapidly
led to the appearance of 
 
32
 
P-labeled 32S pre-rRNA (Fig. 9 A,
lane b
 
 
 
, arrowhead) and to progressive accumulation of 28S
and 18S mature rRNAs (Fig. 9 A, lanes a
 
 
 
–e
 
 
 
). Conversely
in the presence of roscovitine (Fig. 9 B), proper pre-rRNA
processing was not restored and consequently residual 
 
32
 
P
incorporation led to an increase of 
 
32
 
P-labeled 47-46S pre-
rRNAs (Fig. 9 A and B, compare lanes a
 
 
 
–e
 
 
 
). The residual
pre-rRNA processing observed in roscovitine-treated cells
generated weak and unequal amounts of 28S and 18S
rRNAs, showing once again that proper pre-rRNA process-
ing was impaired.
 
Discussion
 
Inhibition of CDK1–cyclin B is sufficient to induce the 
first events of nucleologenesis
 
Nucleoli are dynamic structures undissociable from rDNA
transcription, pre-rRNA processing and ribosome assem-
bly. They disassemble concomitantly with repression of
rDNA transcription, most probably caused by CDK1–cyclin
B-directed phosphorylation of components of the rDNA tran-
scription machinery (Heix et al., 1998; Sirri et al., 1999). As
for pre-rRNA processing, it is as yet unknown whether its ar-
rest occurring at the onset of mitosis (Fan and Penman, 1971)
takes place as a consequence of the arrest of pre-rRNA synthe-
sis or whether it is also regulated. Conversely, rDNA transcrip-
tion is restored in telophase at the level of competent NORs
(Roussel et al., 1996). As reported here, when cells exit from
mitosis restoration of pre-rRNA processing is concomitant
with restoration of rDNA transcription. Interestingly, in vivo
inhibition of the CDK1–cyclin B is sufficient to restore rDNA
transcription in mitotic cells but not pre-rRNA processing
Figure 6. Ultrastructural organization of nucleolus in HeLa cells 
treated with roscovitine (A) or not treated (B). After 30 min in the 
presence of 75  M roscovitine, the DFC is only partly visible (arrow) 
and replaced by new densely packed and highly contrasted material 
that surrounds the FC (A). In this highly contrasted material, granules 
are visible (A, arrowhead). Compare in B the distribution of DFC 
around the FC in normal conditions when rDNA transcription and 
pre-rRNA processing occur. Bar, 0.5  m. 
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(Sirri et al., 2000). Therefore, even if rDNA transcription and
pre-rRNA processing are restored concomitantly at the exit
from mitosis, both are regulated by distinct mechanisms.
Using CDK inhibitors to uncouple restoration of rDNA
transcription and pre-rRNA processing, we tested the prevail-
ing model (Scheer and Weisenberger, 1994), according to
which transcriptionally active rDNAs, serving as nucleation
sites, possess by themselves the ability to organize the nucleoli.
Our results show that rDNA transcription is not sufficient to
induce the formation of nucleoli as demonstrated by phase
contrast observations and by the fact that two nucleolar
marker proteins, fibrillarin and Nop52 do not overlap either
in mitotic cells induced to transcribe or in actively transcrib-
ing early G1 cells previously treated with a CDK inhibitor. In
both cases, fibrillarin is only partly localized at the level of
rDNA transcription sites where nucleoli are expected to form,
and Nop52 appears in bodies corresponding most probably to
PNBs and therefore absent from rDNA transcription sites. At
the exit from mitosis, localization of Nop52 close to the
rDNA transcription sites, i.e., in the reforming nucleoli, is
therefore not (or not entirely) dependent on rDNA transcrip-
tional activity. As to the partial localization of fibrillarin at the
rDNA transcription sites, this is also most probably not due to
rDNA transcriptional activity. Indeed, fibrillarin and nucleo-
lin, both implicated in the early stages of the pre-rRNA pro-
cessing pathway, partly relocalized at NORs at the exit from
mitosis even if rDNA transcription is inhibited by actinomy-
cin D (Dousset et al., 2000). Because fibrillarin and nucleolin
localize at NORs in the absence of rDNA transcription, and
because Nop52 does not localize at NORs after CDK inhibi-
tor treatment in mitotic cells and early G1 cells (albeit they ac-
tively transcribe), we conclude that the formation of func-
tional nucleoli at the exit from mitosis is not governed solely
by the resumption of rDNA transcription.
Our previous results demonstrating that rDNA transcrip-
tion could be reactivated in mitotic cells (Sirri et al., 2000)
Figure 7. CDK inhibitor treatment re-
duces the generation of mature rRNAs. 
Asynchronous interphasic HeLa cells 
were metabolically labeled with 
[
32P]orthophosphate for increasing times 
up to 3 h in the absence or presence of 
CDK inhibitors. RNAs were isolated and 
analyzed. (A) Lanes a–o, RNAs resolved 
on a 1% agarose formaldehyde gel and 
detected by ethidium bromide staining; 
lanes a –o , RNAs detected after 
autoradiography; lanes a–c and a –c , 
cells not treated; lanes d–f and d –f , 
cells treated with 75  M roscovitine; 
lanes g–i and g –i , cells treated with 25 
 M roscovitine; lanes j–l and j –l , cells 
treated with 250  M olomoucine; lanes 
m–o and m –o , cells treated with 250 
 M iso-olomoucine. (B) Quantification 
of the 
32P-labeled partially processed 
47–45S pre-rRNAs and 
32P-labeled 
mature 28S and 18S rRNAs corresponding 
to the representative experiment shown 
in A. The levels of 
32P-labeled mature
rRNAs decreased after roscovitine and 
olomoucine treatments compared with 
control cells but not when cells were 
treated with iso-olomoucine. The level 
of 
32P-labeled 47–45S pre-rRNAs
appeared less affected by CDK 
inhibitor-treatments especially in 75  M 
roscovitine-treated cells (A, compare 
lanes a –c  and d –f , and B, compare 
Control and 75  M Rosc).978 The Journal of Cell Biology | Volume 156, Number 6, 2002
and the present results obtained in the same experimental
conditions suggest that roscovitine treatment makes it possi-
ble to reproduce the first events of nucleologenesis. This cor-
responds to release from mitotic silencing of rDNA tran-
scription, targeting in transcription sites of early pre-rRNA
processing components such as fibrillarin, and recruitment
of late pre-rRNA processing components such as Nop52, in
PNBs. These first events of nucleologenesis are most proba-
bly regulated by inactivation of the CDK1–cyclin B. Indeed,
among the CDKs known to be substantially inhibited by
roscovitine when tested in vitro, the CDK1-cyclin B is the
only kinase active during mitosis (De Azevedo et al., 1997;
Meijer et al., 1997). Moreover, these events normally take
place in telophase when CDK1–cyclin B is inactivated.
A CDK activity is indispensable to form a functional 
nucleolus at the exit from mitosis
In addition to inactivation of CDK1–cyclin B, another
CDK activity seems to be indispensable to promote the last
events of nucleologenesis and to form a functional nucleolus
at the exit from mitosis. Indeed in early G1 phase, cells pro-
ceeding through mitosis in the presence of a CDK inhibitor
exhibit no relocalization of Nop52 to rDNA transcription
sites, no formation of nucleoli, and a defect in pre-rRNA
processing leading to accumulation of 46S pre-rRNA.
Moreover, the CDK inhibitor effects are fully reversible.
Consequently, at the exit from mitosis, a CDK activity
seems indispensable to promote relocalization of the late
pre-rRNA processing components from PNBs to rDNA
transcription sites and to promote formation of functional
nucleoli. Nevertheless, further investigations are necessary to
establish if restoration of pre-rRNA processing only depends
on correct localization of the processing machinery at the
level of rDNA transcription sites or if the processing ma-
chinery must also to be activated. A third possibility would
be that relocalization of late pre-rRNA processing compo-
nents from PNBs to rDNA transcription sites would depend
on activation of early pre-rRNA processing components.
Concerning the identity of the kinase(s) involved in the
formation of functional nucleoli, in addition to CDKs, i.e.,
CDK1–cyclin B, CDK2–cyclin A, CDK2–cyclin E, and
CDK5-p35, the different CDK inhibitors used in this study
inhibit ERK1/2 to a lesser extent. Because U0126, an inhib-
itor of mitogen-activated protein kinase kinase and conse-
quently of ERK1/2, did not affect formation of nucleoli, the
kinase implicated is probably a CDK. Because CDK1–
cyclin B is inactivated when this nucleologenesis-related ki-
nase is to be activated, the remaining candidates are CDK2–
cyclin A, CDK2–cyclin E, and CDK5-p35. Even if CDK2
has not yet been reported as active at the beginning of inter-
Figure 8. Roscovitine treatment leads to accumulation of 46S 
pre-rRNA. (A) Interphasic HeLa cells were metabolically labeled for 
2 h with [
32P]orthophosphate in the absence of roscovitine (lanes a 
and d), and in the presence of 25  M (lanes b and e) or 75  M 
roscovitine (lanes c and f). RNAs were isolated and analyzed. (A) 
Lanes a–c, RNAs detected in 1.2% agarose formaldehyde gel by 
ethidium bromide staining; lanes d–f, RNAs detected after
autoradiography. In a dose-dependent manner, roscovitine treatment 
increased the level of 46S pre-rRNA and reduced the levels of 32S 
pre-rRNA and mature 28S and 18S rRNAs. (B) Interphasic HeLa 
cells were treated for increasing times up to 2 h with 75  M 
roscovitine. RNAs were isolated, resolved on 0.75% agarose 
formaldehyde gels and blotted. The blots were hybridized with a 
32P-labeled 5 -ETS core probe recognizing the 47–45S pre-rRNAs 
(5 ETS core), a 
32P-labeled 3 -ETS probe recognizing both 47S and 
46S pre-rRNAs (3 -ETS), and a 
32P-labeled 5 -ETS leader probe specific 
for the unprocessed 47S pre-rRNA (5 ETS leader). The 45–47S 
pre-rRNAs globally increased with increasing time of treatment and 
the 45S pre-rRNA, only detected by the 5 -ETS core probe (*), rapidly 
disappeared. This increase was also observed with the 3 -ETS but 
not with the 5 ETS leader probe.CDKs govern nucleolar functions | Sirri et al. 979
phase and CDK5 has no known function in proliferative
cells, further investigations are necessary to test the possible
key role played by these CDKs in the formation of nucleoli.
However, it is also possible that the kinase implicated is not
yet characterized as a target of these CDK inhibitors.
A CDK activity is also indispensable to maintain a 
functional nucleolus throughout interphase
Treatment with the highly selective CDK inhibitors, rosco-
vitine, olomoucine, purvalanol, or alsterpaullone modify
both rDNA transcription and pre-rRNA processing, and in-
duce a dramatic but reversible disorganization of active nucle-
oli, whatever the interphase stage of the cells. As expected
from previous results showing that the transcription factor
UBF is regulated by CDKs among which CDK2–cyclin E
(Voit et al., 1999), rDNA transcription decreases after CDK
inhibitor treatment but remains active. Remarkably, in addi-
tion to the decrease in rDNA transcription, these treatments
impair pre-rRNA processing. Even if additional experiments
are necessary to identify the kinase(s) implicated, it seems
most likely that maintaining functional nucleoli implies
CDK(s). Indeed, inhibition of ERK1/2, the only kinase in
addition to CDKs sensitive to each CDK inhibitor used here,
when tested in vitro, caused no obvious effect on nucleoli.
CDK inhibitor treatments do not lead to the accumula-
tion of incorrectly processed rRNAs, but hamper the first
processing events leading to accumulation of 46S pre-rRNA
and disappearance of 45S pre-rRNA. It is noteworthy that
even if rDNA transcription is lowered, the level of 47S pre-
rRNA remains constant. Therefore, the cleavage leading to
the 46S pre-rRNA from the 47S pre-rRNA is most probably
also hampered. Possibly, the complexes involved in the first
cleavages are inhibited or partly inhibited in the presence of
CDK inhibitors and this inhibition might prevent or disturb
subsequent pre-rRNA cleavages by hindering subsequent
protein–protein and/or protein–RNA interactions. It may
also be hypothesized that the cleavages of pre-rRNA are pre-
vented because the pre-rRNA undergoes structural rear-
rangements in the presence of CDK inhibitors or conversely
does not undergo the structural rearrangements required to
be properly and efficiently processed.
How is a nucleolus maintained as a functional domain?
The nucleolus is a highly dynamic domain generated by the
processes necessary to built ribosomes (Mélèse and Xue,
1995). Consequently, nucleolar disorganization is induced
when transcription is inhibited during interphase or during
nucleologenesis (Dousset et al., 2000). This is characterized
by typical features corresponding to segregation of the nu-
cleolar components, FCs, DFC, and GC (Hadjiolov, 1985).
CDK inhibitor treatment results in reorganization of the
DFC, where the first pre-rRNA processing events occur nor-
mally a few seconds after transcription termination (All-
mang et al., 1999), and in the absence of typical GC. These
features suggest that pre-rRNA processing must be achieved
to establish typical DFC and the transition between DFC
and GC. Therefore, the structural organization of nucleoli is
not only determined by rDNA transcription activity, and
Figure 9. Roscovitine-induced defect in pre-rRNA processing is fully reversible. (A and B) Asynchronous interphasic HeLa cells were 
pulse-labeled with [
32P]orthophosphate in the presence of 75  M roscovitine for 2 h. After a chase in nonradioactive medium in the absence 
(A) or presence (B) of 75  M roscovitine for 0 h (A and B, lanes a and a ), 1 h (A and B, lanes b and b ), 2 h (A and B, lanes c and c ), 3 h (A 
and B, lanes d and d ), and 4 h (A and B, lanes e and e ), RNAs were isolated and resolved on a 1% agarose formaldehyde gel. (A and B, lanes 
a–e) Ethidium bromide staining. (A and B, lanes a –e ) Autoradiography. In the absence of roscovitine during the chase, the defect in pre-rRNA 
processing induced by roscovitine was rapidly reversed as shown by the high increase of the 
32P-labeled 32S pre-RNA (A, lane b , arrowhead) 
and mature 28S and 18S rRNAs (A, lane b ). Consequently, the residual synthesis of 
32P-labeled pre-rRNAs led to accumulation of the 
32P-labeled 
mature 28S and 18S rRNAs (A, compare a –e ). Conversely, when the chase was applied in the presence of roscovitine (B), the residual 
synthesis of 
32P-labeled pre-rRNAs led to an increase of 
32P-labeled 47–46S pre-rRNAs (compare A to B, lanes a –e ). Only a slight increase of 
the 28S and 18S rRNAs was observed.980 The Journal of Cell Biology | Volume 156, Number 6, 2002
obviously both rDNA transcription and pre-rRNA process-
ing are required to maintain a nucleolus. It is noteworthy
that CDK inhibition disrupts the highly organized nucleolus
but does not scatter the nucleolar machineries in the nu-
cleus. The rDNA transcription machinery is still active and
the processing machinery is delocalized in nuclear bodies
distributed in the nucleoplasm. Since CDK inhibitor–induced
nucleolus disorganization is rapidly reversible, it is tempting
to propose that the active nucleolus constitutes a functional
nuclear domain whose organization is determined by the dy-
namics of the processes necessary to produce ribosomes, i.e.,
rDNA transcription, pre-rRNA processing and ribosome as-
sembly. The CDK inhibitors could interfere with the steady
state of these processes by blocking key factor(s) involved in
pre-rRNA processing. Another possibility would be to con-
sider a decrease of rDNA clustering modifying the local con-
centration of molecules which normally interact with the
processing machinery and thus locally diminishing the re-
tention of these complexes.
Whatever the mechanism blocked by the CDK inhibitors,
the presence of a fully active nucleolus clearly depends on
cell cycle regulators. Conversely, the important question
concerning the possible role of active nucleoli in the control
of cell cycle progression warrants further investigation.
Materials and methods
Cell culture and synchronization
Stably transfected fibrillarin–green fluorescent protein (GFP) and Nop52-
GFP HeLa cell lines previously reported (Savino et al., 2001) and untrans-
fected HeLa cell line were cultured in MEM supplemented with 10% FCS
and 2 mM L-glutamine (GIBCO BRL). For synchronization in metaphase,
the cells were accumulated in prometaphase by nocodazole treatment
(0.04  g/ml for 4 h), selectively harvested by mechanical shock, washed,
and resuspended in nocodazole-free medium for 30 min where they pro-
gressed into metaphase in a semisynchronous manner. Cells were also
blocked in mitosis by colchicine treatment (0.02  g/ml for 14 h) and mi-
totic cells harvested by mechanical shock. For immunofluorescence and in
situ transcription assays, asynchronous cells were grown as monolayers on
glass slides, and synchronized mitotic cells were transferred onto poly-
L-lysine-coated glass slides.
Kinase inhibitor treatments
Roscovitine, olomoucine, and iso-olomoucine were obtained from Calbio-
chem, U0126 from Promega, and alsterpaullone, and purvalanol (NG97)
was provided by L. Meijer (Station Biologique, Roscoff, France). Synchro-
nized mitotic cells and asynchronous cells were treated with 25 or 75  M
roscovitine, or with 250  M olomoucine or iso-olomoucine for various
times up to 3 h. Alsterpaullone and purvalanol were used on asynchronous
cells at a concentration of 75  M for various times up to 3 h. U0126 was
used on asynchronous cells at concentrations up to 200  M for 3 h.
Antibodies and probes
Antibodies.  The human autoimmune sera with specificity against UBF
(A17) and Nop52 (C13) were described previously (Roussel et al., 1996;
Savino et al., 1999). The human autoimmune serum with specificity
against fibrillarin (O61) was characterized during this study and the mouse
monoclonal anti-fibrillarin was 72B9 (Reimer et al., 1987). The anti-BrdU
antibody was obtained from Sigma-Aldrich. Texas Red–conjugated sec-
ondary antibodies specific for human and mouse IgGs, and FITC-conju-
gated goat anti–human antibodies were obtained from Jackson ImmunoRe-
search Laboratories, Inc.
Probes. The 5 -ETS leader and the 3 -ETS probes correspond to frag-
ments of human rDNA, respectively, 409 nucleotides (nt) downstream
from the initiation site (nt  1/ 410) and 309 nt into the 3 -ETS (nt
 13040/ 13348). These fragments were first amplified by PCR as BamHI-
EcoRI fragments using pBES (Wilson et al., 1982) and pDES (Erickson and
Schmickel, 1985) as template DNAs and inserted into the BamHI/EcoRI
sites of pBluescript SK( ). The 5 -ETS leader and 3 -ETS probes were then
generated by BamHI/EcoRI digestions. The 5 -ETS core probe was a SalI-
SalI fragment of human rDNA (nt  693/ 2921) prepared from pBSS (Wil-
son et al., 1982).
Assay of pol activity in situ and immunofluorescence labeling
Assay of pol activity in situ was performed as previously described in con-
ditions set up to reveal pol I and pol II transcription (Roussel et al., 1996).
Cells were then postfixed in 2% (wt/vol) paraformaldehyde for 20 min at
room temperature (RT) and permeabilized with 0.5% Triton X-100 at RT
for 5 min. Bromo-uridine 5 -triphosphate incorporation was detected by
immunofluorescence labeling using a mouse monoclonal anti-BrdU anti-
body revealed by Texas Red–conjugated goat anti–mouse antibodies. In
addition to bromo-uridine 5 -triphosphate incorporation, fibrillarin and
Nop52 were simultaneously detected using sera O61 and C13, respec-
tively, and revealed by FITC-conjugated goat anti–human antibodies.
For immunofluorescence labeling, cells were also fixed in 2% (wt/vol)
paraformaldehyde for 20 min at RT and permeabilized with 0.5% Triton
X-100 for 5 min. Cells were incubated with sera at RT for 45 min, and the
antibodies were revealed with suitable Texas Red– and/or FITC-conjugated
secondary antibodies. DNA was visualized with DAPI. All preparations
were mounted with the antifading solution Citifluor (Canterbury, UK). Flu-
orescent microscopy was performed using a CCD camera Leitz DMRB and
images assembled using Adobe Photoshop.
Metabolic labeling and RNA analysis
For the analysis of rRNA synthesis in cells proceeding through M/G1
transition, cells were synchronized in metaphase in phosphate-free
MEM. Metaphase-synchronized cells were then metabolically labeled
with [
32P]orthophosphate at a final concentration of 125  Ci/ml (ICN
Biomedicals) in the presence or absence of 75  M roscovitine and RNA
synthesis analyzed every 30 min up to 120 min. Interphasic HeLa cells
were metabolically labeled with [
32P]orthophosphate (125  Ci/ml) in
phosphate-free MEM for various times up to 3 h in the absence or pres-
ence of kinase inhibitor.
For pulse-chase experiments, interphasic cells were pulse labeled with
[
32P]orthophosphate (125  Ci/ml) in phosphate-free MEM for 2 h in the
presence of 75  M roscovitine and chased in nonradioactive medium with
excess phosphate for various times up to 4 h in the presence or absence of
75  M roscovitine.
For 
32P-labeling experiments, total RNAs were isolated using TRI RE-
AGENT (Sigma-Aldrich), and RNAs corresponding to 4   10
5 cells were
separated by electrophoresis on 1–1.2% agarose formaldehyde gels. The
RNAs were transferred to positively charged membranes (Roche). After UV
cross-linking, autoradiographies were performed with a PhosphorImager
(Molecular Dynamics, Inc.) and quantifications of 
32P-labeled rRNAs using
NIH Image software.
For Northern blot analyses, total RNAs were isolated from interphasic
cells treated with 75  M roscovitine for various times from 0 to 2 h using
TRI REAGENT. RNAs corresponding to 5   10
5 cells were separated in
0.75% agarose formaldehyde gels and transferred to positively charged
membranes. The rDNA probes were labeled with [ 
32P]dCTP by nick
translation (GIBCO BRL). Hybridization with the radiolabeled probes was
carried out as previously described (Sirri et al., 2000). Autoradiographies
were performed with a PhosphorImager and quantifications using NIH Im-
age software.
Transmission electron microscopy
Cells treated or not with 75  M roscovitine for 0.5, 1, or 2 h were fixed in
2.5% (vol/vol) glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4,
at 4 C for 1 h, rinsed, postfixed in 1% (wt/vol) osmium tetroxide in the
same buffer for 30 min, dehydrated, and embedded in Epon 812. After
resin polymerization, ultrathin sections were conventionally contrasted
with uranyl acetate (30 min) followed by lead citrate (10 min) and exam-
ined in a Philips CM12 electron microscope.
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